GSK and UK reach swine flu Pandemrix deal
This article was originally published in Scrip
The UK’s Department of Health has capped UK orders of GlaxoSmithKline's A (H1N1) vaccine Pandemrix at 34.8 million doses, it said yesterday as swine flu cases have reached their lowest levels yet.
You may also be interested in...
Advicenne withdrew its orphan drug designation application for Sibnayal over concerns that a key study was not designed to compare the product to standard of care.
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.